Medicare Enrolled
Dr. Vasia Ahmed, M.D.
Medical Oncology · Tinley Park, IL
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Ahmed from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Ahmed?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Ahmed
Dr. Vasia Ahmed is a medical oncology specialist in Tinley Park, IL, with 20 years of NPI registration. Based on federal Medicare data, Dr. Ahmed performed 85,553 Medicare services across 1,696 unique beneficiaries.
Between the years covered by Open Payments, Dr. Ahmed received a total of $17,370 from 76 pharmaceutical and/or device companies across 677 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Ahmed is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 11% volume in IL
$17,370 industry payments
Medicare Practice Summary
Medicare Utilization ↗85,553
Medicare services
Top 11% in IL for medical oncology
1,696
Unique beneficiaries
$10
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~4,278 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
36,750 | $1 | $5 |
| Darbepoetin injection (Aranesp) for anemia An injection of darbepoetin alfa used for non-end-stage renal disease purposes. |
16,870 | $2 | $21 |
| Pembrolizumab injection (Keytruda) | 9,800 | $43 | $147 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
9,300 | $0 | $7 |
| Denosumab injection (Prolia/Xgeva) | 2,820 | $19 | $70 |
| Rituximab-pvvr biosimilar injection, 10 mg An injection of rituximab-pvvr, a biosimilar medication, administered in a 10 mg dose. |
2,170 | $22 | $194 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,606 | $0 | $2 |
| Injection, leucovorin calcium, per 50 mg | 924 | $3 | $52 |
| Anti-nausea injection (Aloxi/palonosetron) | 910 | $1 | $122 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
550 | $96 | $397 |
| Fluorouracil injection, 500 mg Administration of a 500 mg dose of fluorouracil medication via injection. |
492 | $2 | $14 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
419 | $99 | $370 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
320 | $136 | $523 |
| Pegfilgrastim injection, 0.5 mg An injection of pegfilgrastim, a medication that stimulates the production of white blood cells. This specific code applies to the brand-name drug and excludes biosimilar versions. |
288 | $82 | $1,444 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
285 | $11 | $93 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
264 | $13 | $105 |
| Injection, granisetron hydrochloride, 100 mcg | 250 | $0 | $25 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
230 | $2 | $300 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
204 | $108 | $686 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
137 | $24 | $152 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
136 | $143 | $743 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
85 | $54 | $334 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
73 | $53 | $304 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
72 | $23 | $156 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
70 | $1 | $7 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
66 | $1 | $19 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
64 | $17 | $97 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
54 | $30 | $240 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
53 | $60 | $205 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
41 | $68 | $270 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
36 | $45 | $281 |
| IV chemotherapy initiation with community continuation Initiation of an intravenous chemotherapy infusion in a clinic using clinic supplies, with continuation of the infusion in a community setting such as home or assisted living. |
36 | $213 | $986 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
33 | $20 | $111 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
31 | $16 | $91 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
27 | $66 | $262 |
| New patient office visit, complex (60-74 min) | 23 | $121 | $760 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
22 | $51 | $620 |
| Nuclear medicine scan from skull base to mid-thigh with CT A nuclear medicine imaging study covering the area from the base of the skull to the middle of the thighs, performed alongside a CT scan. |
21 | $1,300 | $4,120 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 21 | $410 | $638 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
43.7% high complexity
54.5% medium
1.9% routine
Industry Payment Transparency
Open Payments through 2024 ↗$17,370
Total received (2018-2024)
Avg $2,481/year across 7 years
Top 22% in IL for medical oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
76
Companies
677
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$12,184 (70.1%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$2,283 (13.1%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$1,749 (10.1%)
Other
Charitable contributions, space rental, and other categories
$1,154 (6.6%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$2,217
2023
$1,955
2022
$2,109
2021
$2,089
2020
$1,282
2019
$2,426
2018
$5,292
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Gilead Sciences, Inc.
$272
PFIZER INC.
$253
Lilly USA, LLC
$241
Novartis Pharmaceuticals Corporation
$180
Alexion Pharmaceuticals, Inc.
$143
ABBVIE INC.
$123
Merck Sharp & Dohme LLC
$113
Takeda Pharmaceuticals U.S.A., Inc.
$99
GlaxoSmithKline, LLC.
$75
Blueprint Medicines Corporation
$67
AstraZeneca Pharmaceuticals LP
$67
Astellas Pharma US Inc
$67
Regeneron Healthcare Solutions, Inc.
$54
Genentech USA, Inc.
$43
E.R. Squibb & Sons, L.L.C.
$42
SpringWorks Therapeutics, Inc.
$40
Janssen Biotech, Inc.
$40
Eisai Inc.
$38
Incyte Corporation
$32
Genmab U.S., Inc.
$28
Sumitomo Pharma America, Inc.
$28
EMD Serono, Inc.
$27
Daiichi Sankyo Inc.
$26
Mirati Therapeutics, Inc.
$25
RECORDATI_RARE_DISEASES_INC.
$24
Amgen Inc.
$20
SOBI, INC
$18
Tempus AI, Inc
$18
Janssen Pharmaceuticals, Inc
$14
Top 3 companies account for 34.6% of 2024 payments
All-time payments by company (2018-2024) ›
Exelixis Inc.
$1,867
Celgene Corporation
$1,469
Novartis Pharmaceuticals Corporation
$1,411
AstraZeneca Pharmaceuticals LP
$961
E.R. Squibb & Sons, L.L.C.
$898
Merck Sharp & Dohme Corporation
$836
PFIZER INC.
$791
Incyte Corporation
$772
Amgen Inc.
$750
Gilead Sciences, Inc.
$622
Janssen Biotech, Inc.
$606
Lilly USA, LLC
$570
Genentech USA, Inc.
$405
Merck Sharp & Dohme LLC
$385
Takeda Pharmaceuticals U.S.A., Inc.
$310
TESARO, Inc.
$293
Bayer HealthCare Pharmaceuticals Inc.
$231
Eisai Inc.
$209
Astellas Pharma US Inc
$200
GlaxoSmithKline, LLC.
$196
Regeneron Healthcare Solutions, Inc.
$190
Pharmacyclics LLC, An AbbVie Company
$182
Seagen Inc.
$179
Dova Pharmaceuticals
$170
NOVARTIS PHARMACEUTICALS CORPORATION
$167
GENZYME CORPORATION
$163
EMD Serono, Inc.
$158
Alexion Pharmaceuticals, Inc.
$156
Puma Biotechnology, Inc.
$139
Daiichi Sankyo Inc.
$136
ABBVIE INC.
$123
Janssen Pharmaceuticals, Inc
$118
AbbVie, Inc.
$110
Seattle Genetics, Inc.
$105
Covidien LP
$101
G1 Therapeutics, Inc.
$92
Sobi, Inc
$73
JAZZ PHARMACEUTICALS INC.
$70
AbbVie Inc.
$68
Blueprint Medicines Corporation
$67
SANOFI-AVENTIS U.S. LLC
$60
Kite Pharma, Inc.
$58
TerSera Therapeutics LLC
$53
ARRAY BIOPHARMA INC
$52
Rigel Pharmaceuticals, Inc.
$52
Immunomedics, Inc.
$44
BeiGene USA, Inc.
$44
MorphoSys, US Inc.
$41
SpringWorks Therapeutics, Inc.
$40
ADC Therapeutics America, Inc.
$38
Jazz Pharmaceuticals Inc.
$35
Boehringer Ingelheim Pharmaceuticals, Inc.
$33
Kyowa Kirin, Inc.
$29
Genmab U.S., Inc.
$28
Sumitomo Pharma America, Inc.
$28
Mirati Therapeutics, Inc.
$25
Aveo Pharmaceuticals, Inc.
$24
RECORDATI_RARE_DISEASES_INC.
$24
Pharmacyclics LLC, an AbbVie Company
$23
EISAI INC.
$22
R-Pharm US LLC
$21
Ipsen Biopharmaceuticals, Inc
$21
Epizyme, Inc.,
$20
Novo Nordisk Inc
$20
Aurobindo Pharma USA, Inc.
$19
Fortovia Therapeutics, Inc.
$19
TOLMAR Pharmaceuticals, Inc.
$18
SOBI, INC
$18
Tempus AI, Inc
$18
Bayer Healthcare Pharmaceuticals Inc.
$17
Medtronic USA, Inc.
$15
Karyopharm Therapeutics Inc.
$14
Array BioPharma Inc.
$14
Verastem, Inc.
$13
Nestle HealthCare Nutrition Inc.
$13
Mylan Institutional Inc.
$12
Top 3 companies account for 27.3% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · ALIMTA · ALUNBRIG · AYVAKIT · Abraxane · Alecensa · Avastin · BAVENCIO · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Balversa · Barrx · Bavencio · Braftovi · CABOMETYX · CALQUENCE · CHANTIX · COSELA · CYRAMZA · Cabometyx · Columvi · Copiktra · DARZALEX · DOPTELET · Doptelet · ELAHERE · ELIGARD · ELIQUIS · ELITEK · EMPLICITI · ENHERTU · EPKINLY · ERBITUX · ERLEADA · Enhertu · Epkinly · Erleada · FOTIVDA · Fabhalta · Fulphila · GAZYVA · GILOTRIF · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INLYTA · Imbruvica · Ixempra · JADENU · JAKAFI · JEMPERLI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lunsumio · MEKINIST · MONJUVI · MVASI · NINLARO · Nerlynx · Neulasta · Nplate · Nubeqa · OGSIVEO · OJJAARA · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · OSTEOCOOL RF ABLATION · OXBRYTA · Ocrevus · PADCEV · PIQRAY · PLUVICTO · POTELIGEO · PROMACTA · PROSTATE CANCER - DISEASE · Padcev · Perjeta · Pomalyst · Prolia · REBLOZYL · Revlimid · SANCUSO · SARCLISA · SCEMBLIX · SOLIRIS · SUTENT · SYLVANT · Somatuline Depot · Stivarga · TABRECTA · TASIGNA · TAZVERIK · TECENTRIQ · TUKYSA · Tavalisse · Trodelvy · ULTOMIRIS · VENCLEXTA · VERZENIO · VONJO · Venclexta · Victoza · Vitrakvi · XALKORI · XARELTO · XGEVA · XPOVIO · XTANDI · Xermelo · Xofigo · ZEJULA · ZENPEP · ZEPZELCA · ZOLADEX · Zevalin
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (70%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Medical oncologists within 10 mi
38
Per 100K population
0.7
County median income
$81,797
Nearest hospital
PALOS COMMUNITY HOSPITAL
7.1 mi
7.1 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Ahmed is a mixed practice specialist, with above-average Medicare volume (top 11% in IL), with low-engagement industry engagement, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Ahmed experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Ahmed performed 36,750 iron infusion (injectafer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Ahmed receive payments from pharmaceutical companies?
Yes. Dr. Ahmed received a total of $17,370 from 76 companies across 677 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Ahmed's costs compare to other medical oncologists in Tinley Park?
Dr. Ahmed's average Medicare payment per service is $10. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Ahmed) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in Tinley Park
Browse medical oncologists in Tinley Park ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in IL
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in IL
Which IL medical oncologists receive the most from drug and device companies.
By company
Exelixis Inc. Payments to Doctors
See all physicians who received payments from Exelixis Inc.
By company
Celgene Corporation Payments to Doctors
See all physicians who received payments from Celgene Corporation.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology